GlassScriptPhysician profile
Ruma Rajbhandari
NPI 1003008244
$2,727.77
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $324 · 2021: $1,514 · 2022: $95.44.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $617.33 | 2019-2021 | |
| Abbvie INC. | $558.53 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $406.14 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $404.65 | 2019-2022 | |
| Gilead Sciences, INC. | $185.75 | 2019-2021 | |
| Celgene Corporation | $124.27 | 2021 | |
| Ferring Pharmaceuticals INC. | $97.99 | 2019-2020 | |
| Pfizer INC. | $90.59 | 2019 | |
| Ironwood Pharmaceuticals, INC | $48.51 | 2021 | |
| Intercept Pharmaceuticals, INC. | $41.32 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $39.00 | 2021 | |
| Alfasigma USA, INC. | $19.03 | 2020 | |
| Shire North American Group INC | $18.40 | 2019 | |
| Janssen Biotech, INC. | $18.10 | 2019 | |
| Echosens North America, INC. | $16.78 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $16.02 | 2019 | |
| Ucb, INC. | $13.51 | 2020 | |
| Endo Pharmaceuticals INC. | $11.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruma Rajbhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.